Treatment of Paraneoplastic Cerebellar Degeneration
- 13 January 2013
- journal article
- Published by Springer Science and Business Media LLC in Current Treatment Options in Neurology
- Vol. 15 (2), 185-200
- https://doi.org/10.1007/s11940-012-0215-4
Abstract
Paraneoplastic cerebellar degeneration is an uncommon autoimmune disorder characterized clinically by progressive, ultimately incapacitating ataxia and pathologically by destruction of cerebellar Purkinje cells, with variable loss of other cell populations. The disorder is most commonly associated with gynecological and breast carcinomas, small cell carcinoma of the lung, and Hodgkin’s disease and in most cases comes on prior to identification of the underlying neoplasm. The hallmark of paraneoplastic cerebellar degeneration is the presence of an immune response reactive with intracellular proteins of Purkinje or other neurons or, less commonly, against neuronal surface antigens. Evidence-based treatment strategies for paraneoplastic cerebellar degeneration do not exist; and approaches to therapy are thus speculative. Diagnosis and treatment of the underlying neoplasm is critical, and characterization of the antibody response involved may assist in tumor diagnosis. Most investigators have initiated treatment with corticosteroids, plasma exchange, or intravenous immunoglobulin G. Cyclophosphamide, tacrolimus, rituximab, or possibly mycophenolate mofetil may warrant consideration in patients who fail to stabilize or improve on less aggressive therapies. Plasma exchange has been of questionable benefit when used alone but should be considered at initiation of treatment to achieve rapid lowering of circulating paraneoplastic autoantibodies. Because the course of illness is one of relentless neuronal destruction, time is of the essence in initiating treatment. Likelihood of clinical improvement in patients with longstanding symptoms and extensive neuronal loss is poor.Keywords
This publication has 89 references indexed in Scilit:
- Central nervous system neuronal surface antibody associated syndromes: review and guidelines for recognitionJournal of Neurology, Neurosurgery & Psychiatry, 2012
- Neutropenia after rituximab treatmentCurrent Opinion in Hematology, 2012
- Extensive herpes zoster involvement following mycophenolate mofetil therapy for sarcoidosisJournal of Ophthalmic Inflammation and Infection, 2011
- Proteasome Inhibition with Bortezomib Depletes Plasma Cells and Autoantibodies in Experimental Autoimmune Myasthenia GravisThe Journal of Immunology, 2011
- Impact of rituximab-associated B-cell defects on West Nile virus meningoencephalitis in solid organ transplant recipientsClinical Transplantation, 2009
- Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports projectBlood, 2009
- Paraneoplastic syndromes of the CNSThe Lancet Neurology, 2008
- Complications of therapeutic plasma exchange: A prospective study of 1,727 proceduresJournal of Clinical Apheresis, 2007
- Rituximab reduces B cells and T cells in cerebrospinal fluid of multiple sclerosis patientsJournal of Neuroimmunology, 2006
- Intravenous immunoglobulins in neurological disorders: safety issuesNeurological Sciences, 2003